United States Insulin Delivery Market Outlook to 2033

1.1 List of Tables
1.2 List of Figures

2.1 What Is This Report About?
2.2 Insulin Delivery Market Segmentation
2.3 Definitions of Markets Covered in the Report

3.1 Insulin Delivery Market, United States, Revenue ($m), 2018-2033
3.1.1 Insulin Pens Market, United States, Revenue ($m), by Segment, 2018-2033
3.1.2 Insulin Pumps Market, United States, Revenue ($m), by Segment, 2018-2033
3.2 Insulin Delivery Market, United States, Volume (Units), 2018-2033
3.2.1 Insulin Pens Market, United States, Volume (Units), by Segment, 2018-2033
3.2.2 Insulin Pumps Market, United States, Volume (Units), by Segment, 2018-2033
3.3 Insulin Delivery Market, United States, Average Price ($) , 2018-2033
3.4 Insulin Delivery Market, United States, Distribution Share by Revenue ($m), 2023
3.5 Insulin Delivery Market, United States, Company Share by Revenue ($m), 2023

4.1 Eli Lilly and Co
4.1.1 Company Overview
4.2 Novo Nordisk AS
4.2.1 Company Overview
4.3 Medtronic Plc
4.3.1 Company Overview
4.4 Sanofi
4.4.1 Company Overview
4.5 Insulet Corp
4.5.1 Company Overview
4.6 Tandem Diabetes Care Inc
4.6.1 Company Overview

6.1 Debt Offerings
6.1.1 Eli Lilly Raises USD750 Million in Public Offering of 4.150% Notes due 2027
6.1.2 Eli Lilly Raises USD1 Billion in Public Offering of 4.2% Notes due 2029

7.1 Corporate Communications
7.1.1 Mar 06, 2024: Tandem Diabetes Care Prices Upsized Private Placement of $275.0 Million of Convertible Senior Notes Due 2029
7.1.2 Mar 04, 2024: Tandem Diabetes Care Announces Proposed Private Placement of Convertible Notes
7.1.3 Mar 04, 2024: Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
7.2 Financial Announcements
7.2.1 Nov 07, 2024: Nektar Therapeutics Reports Third Quarter 2024 Financial Results
7.2.2 Oct 31, 2024: MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
7.2.3 Oct 16, 2024: Lilly Confirms Date and Conference Call for Third-Quarter 2024 Financial Results Announcement
7.2.4 Oct 10, 2024: BD to Announce its Fiscal 2024 Fourth Quarter and Full Year Financial Results
7.2.5 Sep 26, 2024: Integer Schedules Third Quarter 2024 Earnings Release and Conference Call for October 24, 2024
7.2.6 Jul 03, 2024: BD to Announce Financial Results for its Third Quarter of Fiscal 2024
7.2.7 Jun 04, 2024: Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
7.2.8 May 01, 2024: MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
7.2.9 Apr 16, 2024: Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results
7.2.10 Apr 03, 2024: Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024
7.2.11 Feb 20, 2024: MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
7.3 Government and Public Interest
7.3.1 Oct 04, 2024: Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference
7.3.2 Apr 24, 2024: Merus Announces Presentation MCLA-129 at the 2024 ASCO Annual Meeting
7.3.3 Apr 22, 2024: Johnson & Johnson to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC)
7.3.4 Apr 02, 2024: Johnson & Johnson to Participate in the BofA Securities Health Care Conference
7.3.5 Mar 04, 2024: Biden-Harris Administration Receives Counteroffers from Drug Companies as Part of Ongoing Negotiations to Lower Drug Prices
7.3.6 Feb 14, 2024: Johnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare Conference
7.3.7 Feb 13, 2024: Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors Conference
7.4 Legal And Regulatory
7.4.1 Aug 14, 2024: Enrollment Completed in Phase 3 Clinical Study of Disitamab Vedotin Combined with PD-1 Inhibitor as First-Line Treatment for Urothelial Carcinoma
7.5 Product News
7.5.1 Mar 06, 2024: embecta-sponsored Educational Symposium and Abstracts at ATTD Highlight Role of Insulin Pumps in the Management of Type 2 Diabetes

8.1 Research Methodology
8.1.1 Coverage
8.1.2 Secondary Research
8.1.3 Primary Research
8.1.4 Market Modeling and Forecasting
8.1.5 Company Share Analysis
8.1.6 Distribution Share Analysis
8.1.7 Benchmarking
8.2 the analyst Consulting
8.3 Contact the Publisher
8.4 Disclaimer

Table 1: Insulin Delivery Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 2: Insulin Pens Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 3: Insulin Pumps Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 4: Insulin Delivery Market, United States, Volume (Units), 2018-2033
Table 5: Insulin Pens Market, United States, Volume (Units), 2018-2033
Table 6: Insulin Pumps Market, United States, Volume (Units), 2018-2033
Table 7: Insulin Delivery Market, United States, Average Price ($), 2018-2033
Table 8: Insulin Delivery Market, United States, Distribution Share by Revenue ($m), USD Constant, 2023
Table 9: Insulin Delivery Market, United States, Company Share by Revenue ($m), USD Constant, 2023
Table 10: Insulin Delivery Market Pipeline Products
Table 11: Eli Lilly Raises USD750 Million in Public Offering of 4.150% Notes due 2027
Table 12: Eli Lilly Raises USD1 Billion in Public Offering of 4.2% Notes due 2029

Figure 1: Insulin Delivery Market, United States, Revenue ($m), USD Constant, 2018-2033
Figure 2: Insulin Pens Market, United States, Revenue ($m), USD Constant, 2018-2033
Figure 3: Insulin Pumps Market, United States, Revenue ($m), USD Constant, 2018-2033
Figure 4: Insulin Delivery Market, United States, Volume (Units), 2018-2033
Figure 5: Insulin Pens Market, United States, Volume (Units), 2018-2033
Figure 6: Insulin Pumps Market, United States, Volume (Units), 2018-2033
Figure 7: Insulin Delivery Market, United States, Company Share (%) 2023